The impact of EpCAM expression on response to chemotherapy and clinical outcomes in patients with epithelial ovarian cancer

Shingo Tayama, Takeshi Motohara, Dashdemberel Narantuya, Chenyan Li, Koichi Fujimoto, Isao Sakaguchi, Hironori Tashiro, Hideyuki Saya, Osamu Nagano, Hidetaka Katabuchi

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

Epithelial ovarian cancer is a highly lethal malignancy; moreover, overcoming chemoresistance is the major challenging in treating ovarian cancer patients. The cancer stem cell (CSC) hypothesis considers CSCs to be the main culprits in driving tumor initiation, metastasis, and resistance to conventional therapy. Although growing evidence suggest that CSCs are responsible for chemoresistance, the contribution of CSC marker EpCAM to resistance to chemotherapy remains unresolved. Here we have demonstrated that ovarian cancers containing high levels of EpCAM have a significantly much lower probability of achieving overall responsive rates after first-line chemotherapy. In addition, multivariate analysis revealed that EpCAM expression is an independent risk factor for chemoresistance, indicating that EpCAM expression is a predictive biomarker of chemotherapeutic response. Consistent with these clinical observations, in vitro assays, we found that the subpopulation of EpCAMpositive ovarian cancer cells shows a significantly higher viability compared with EpCAM-negative cells in response to cisplatin treatment by preventing chemotherapyinduced apoptosis, which is regulated by EpCAM-Bcl-2 axis. Furthermore, in an in vivo mouse model, platinum agents preferentially eliminated EpCAM-negative cells in comparison with EpCAM-positive cells, suggesting that the remaining subpopulation of EpCAM-positive cells contributes to tumor recurrence after chemotherapy. Finally, we also found that an increased expression of EpCAM is associated with poor prognosis in ovarian cancer patients. Our findings highlight the clinical significance of EpCAM in the resistance to chemotherapy and provide a rationale for EpCAM-targeted therapy to improve chemoresistance. Targeting EpCAM should be a promising approach to effectively extirpate the CSCs as the putative root of ovarian cancer.

Original languageEnglish
Pages (from-to)44312-44325
Number of pages14
JournalOncotarget
Volume8
Issue number27
DOIs
Publication statusPublished - 2017

Fingerprint

Drug Therapy
Ovarian Neoplasms
Neoplastic Stem Cells
Epithelial Cell Adhesion Molecule
Ovarian epithelial cancer
Neoplasms
Platinum
Cisplatin
Therapeutics
Multivariate Analysis
Biomarkers
Apoptosis
Neoplasm Metastasis
Recurrence

Keywords

  • Cancer stem cell
  • Chemoresistance
  • EpCAM
  • Ovarian cancer
  • Prognosis

ASJC Scopus subject areas

  • Oncology

Cite this

Tayama, S., Motohara, T., Narantuya, D., Li, C., Fujimoto, K., Sakaguchi, I., ... Katabuchi, H. (2017). The impact of EpCAM expression on response to chemotherapy and clinical outcomes in patients with epithelial ovarian cancer. Oncotarget, 8(27), 44312-44325. https://doi.org/10.18632/oncotarget.17871

The impact of EpCAM expression on response to chemotherapy and clinical outcomes in patients with epithelial ovarian cancer. / Tayama, Shingo; Motohara, Takeshi; Narantuya, Dashdemberel; Li, Chenyan; Fujimoto, Koichi; Sakaguchi, Isao; Tashiro, Hironori; Saya, Hideyuki; Nagano, Osamu; Katabuchi, Hidetaka.

In: Oncotarget, Vol. 8, No. 27, 2017, p. 44312-44325.

Research output: Contribution to journalArticle

Tayama, S, Motohara, T, Narantuya, D, Li, C, Fujimoto, K, Sakaguchi, I, Tashiro, H, Saya, H, Nagano, O & Katabuchi, H 2017, 'The impact of EpCAM expression on response to chemotherapy and clinical outcomes in patients with epithelial ovarian cancer', Oncotarget, vol. 8, no. 27, pp. 44312-44325. https://doi.org/10.18632/oncotarget.17871
Tayama, Shingo ; Motohara, Takeshi ; Narantuya, Dashdemberel ; Li, Chenyan ; Fujimoto, Koichi ; Sakaguchi, Isao ; Tashiro, Hironori ; Saya, Hideyuki ; Nagano, Osamu ; Katabuchi, Hidetaka. / The impact of EpCAM expression on response to chemotherapy and clinical outcomes in patients with epithelial ovarian cancer. In: Oncotarget. 2017 ; Vol. 8, No. 27. pp. 44312-44325.
@article{34b3ae725cce42089ad9e0023fb64f48,
title = "The impact of EpCAM expression on response to chemotherapy and clinical outcomes in patients with epithelial ovarian cancer",
abstract = "Epithelial ovarian cancer is a highly lethal malignancy; moreover, overcoming chemoresistance is the major challenging in treating ovarian cancer patients. The cancer stem cell (CSC) hypothesis considers CSCs to be the main culprits in driving tumor initiation, metastasis, and resistance to conventional therapy. Although growing evidence suggest that CSCs are responsible for chemoresistance, the contribution of CSC marker EpCAM to resistance to chemotherapy remains unresolved. Here we have demonstrated that ovarian cancers containing high levels of EpCAM have a significantly much lower probability of achieving overall responsive rates after first-line chemotherapy. In addition, multivariate analysis revealed that EpCAM expression is an independent risk factor for chemoresistance, indicating that EpCAM expression is a predictive biomarker of chemotherapeutic response. Consistent with these clinical observations, in vitro assays, we found that the subpopulation of EpCAMpositive ovarian cancer cells shows a significantly higher viability compared with EpCAM-negative cells in response to cisplatin treatment by preventing chemotherapyinduced apoptosis, which is regulated by EpCAM-Bcl-2 axis. Furthermore, in an in vivo mouse model, platinum agents preferentially eliminated EpCAM-negative cells in comparison with EpCAM-positive cells, suggesting that the remaining subpopulation of EpCAM-positive cells contributes to tumor recurrence after chemotherapy. Finally, we also found that an increased expression of EpCAM is associated with poor prognosis in ovarian cancer patients. Our findings highlight the clinical significance of EpCAM in the resistance to chemotherapy and provide a rationale for EpCAM-targeted therapy to improve chemoresistance. Targeting EpCAM should be a promising approach to effectively extirpate the CSCs as the putative root of ovarian cancer.",
keywords = "Cancer stem cell, Chemoresistance, EpCAM, Ovarian cancer, Prognosis",
author = "Shingo Tayama and Takeshi Motohara and Dashdemberel Narantuya and Chenyan Li and Koichi Fujimoto and Isao Sakaguchi and Hironori Tashiro and Hideyuki Saya and Osamu Nagano and Hidetaka Katabuchi",
year = "2017",
doi = "10.18632/oncotarget.17871",
language = "English",
volume = "8",
pages = "44312--44325",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals",
number = "27",

}

TY - JOUR

T1 - The impact of EpCAM expression on response to chemotherapy and clinical outcomes in patients with epithelial ovarian cancer

AU - Tayama, Shingo

AU - Motohara, Takeshi

AU - Narantuya, Dashdemberel

AU - Li, Chenyan

AU - Fujimoto, Koichi

AU - Sakaguchi, Isao

AU - Tashiro, Hironori

AU - Saya, Hideyuki

AU - Nagano, Osamu

AU - Katabuchi, Hidetaka

PY - 2017

Y1 - 2017

N2 - Epithelial ovarian cancer is a highly lethal malignancy; moreover, overcoming chemoresistance is the major challenging in treating ovarian cancer patients. The cancer stem cell (CSC) hypothesis considers CSCs to be the main culprits in driving tumor initiation, metastasis, and resistance to conventional therapy. Although growing evidence suggest that CSCs are responsible for chemoresistance, the contribution of CSC marker EpCAM to resistance to chemotherapy remains unresolved. Here we have demonstrated that ovarian cancers containing high levels of EpCAM have a significantly much lower probability of achieving overall responsive rates after first-line chemotherapy. In addition, multivariate analysis revealed that EpCAM expression is an independent risk factor for chemoresistance, indicating that EpCAM expression is a predictive biomarker of chemotherapeutic response. Consistent with these clinical observations, in vitro assays, we found that the subpopulation of EpCAMpositive ovarian cancer cells shows a significantly higher viability compared with EpCAM-negative cells in response to cisplatin treatment by preventing chemotherapyinduced apoptosis, which is regulated by EpCAM-Bcl-2 axis. Furthermore, in an in vivo mouse model, platinum agents preferentially eliminated EpCAM-negative cells in comparison with EpCAM-positive cells, suggesting that the remaining subpopulation of EpCAM-positive cells contributes to tumor recurrence after chemotherapy. Finally, we also found that an increased expression of EpCAM is associated with poor prognosis in ovarian cancer patients. Our findings highlight the clinical significance of EpCAM in the resistance to chemotherapy and provide a rationale for EpCAM-targeted therapy to improve chemoresistance. Targeting EpCAM should be a promising approach to effectively extirpate the CSCs as the putative root of ovarian cancer.

AB - Epithelial ovarian cancer is a highly lethal malignancy; moreover, overcoming chemoresistance is the major challenging in treating ovarian cancer patients. The cancer stem cell (CSC) hypothesis considers CSCs to be the main culprits in driving tumor initiation, metastasis, and resistance to conventional therapy. Although growing evidence suggest that CSCs are responsible for chemoresistance, the contribution of CSC marker EpCAM to resistance to chemotherapy remains unresolved. Here we have demonstrated that ovarian cancers containing high levels of EpCAM have a significantly much lower probability of achieving overall responsive rates after first-line chemotherapy. In addition, multivariate analysis revealed that EpCAM expression is an independent risk factor for chemoresistance, indicating that EpCAM expression is a predictive biomarker of chemotherapeutic response. Consistent with these clinical observations, in vitro assays, we found that the subpopulation of EpCAMpositive ovarian cancer cells shows a significantly higher viability compared with EpCAM-negative cells in response to cisplatin treatment by preventing chemotherapyinduced apoptosis, which is regulated by EpCAM-Bcl-2 axis. Furthermore, in an in vivo mouse model, platinum agents preferentially eliminated EpCAM-negative cells in comparison with EpCAM-positive cells, suggesting that the remaining subpopulation of EpCAM-positive cells contributes to tumor recurrence after chemotherapy. Finally, we also found that an increased expression of EpCAM is associated with poor prognosis in ovarian cancer patients. Our findings highlight the clinical significance of EpCAM in the resistance to chemotherapy and provide a rationale for EpCAM-targeted therapy to improve chemoresistance. Targeting EpCAM should be a promising approach to effectively extirpate the CSCs as the putative root of ovarian cancer.

KW - Cancer stem cell

KW - Chemoresistance

KW - EpCAM

KW - Ovarian cancer

KW - Prognosis

UR - http://www.scopus.com/inward/record.url?scp=85021815342&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85021815342&partnerID=8YFLogxK

U2 - 10.18632/oncotarget.17871

DO - 10.18632/oncotarget.17871

M3 - Article

AN - SCOPUS:85021815342

VL - 8

SP - 44312

EP - 44325

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 27

ER -